ConductScience.org, home

Gene · 9221

NOLC1: nucleolar and coiled-body phosphoprotein 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. NOLC1: nucleolar and coiled-body phosphoprotein 1. Genes, record 9221. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9221

On this page

Gene

Symbol
NOLC1
HGNC
Name
nucleolar and coiled-body phosphoprotein 1
HGNC
NCBI Gene ID
9221
NCBI Gene
HGNC ID
HGNC:15608
HGNC
Ensembl
ENSG00000166197
NCBI Gene
Aliases
KIAA0035, NOPP130, NOPP140, NS5ATP13, P130, Srp40
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q14978Nucleolar and coiled-body phosphoprotein 16990Ensembl, GeneID, HGNC

Source UniProt

Patents15

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4650780 A22025-11-1918122Q14978Espacenet
EP 4641201 A22025-10-2922504Q14978Espacenet
EP 4641202 A22025-10-299302Q14978Espacenet
JP 2025517969 A2025-06-1222504Q14978Espacenet
JP 2025517970 A2025-06-1218122Q14978Espacenet
KR 1020250017231 A2025-02-049302Q14978Espacenet
US 11564998 B22023-01-316236Q14978Espacenet
US 11446398 B22022-09-2058682Q14978Espacenet
JP 2022524081 A2022-04-27161653Q14978Espacenet
WO 2020043864 A12020-03-051668Q14978Espacenet

1 to 10 of 15

See all 15 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,224

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleNOLC1 papersNewest fiscal year
R01ES005775Oncometabolites, DNA Repair, and Cancer72025
P30CA008748Cancer Center Support Grant62025
P30CA016672Cancer Center Support Grant62025
P30CA006927Comprehensive Cancer Center Program at Fox Chase52025
P30CA016087Cancer Center Support Grant52025
P30CA125123Baylor College of Medicine Cancer Center - Cancer Center Support Grant52025
P30CA014599Cancer Center Support Grant42025
P30CA068485Cancer Center Support Grant42025
P30CA093373Cancer Center Support Grant P3042025
ZIAHD000196Phosphoinositide-calcium Signaling In Cell Regulation42025

1 to 10 of 1,224Source NIH's project files

See all 1,224 nih grants

Papers1,561

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.Transl Oncol202642822321PubTator, text miningPubMed
The p53-Associated Regulation of ATF4 mRNA Expression Involves p21 and p130 in a Stress-Dependent Manner.Cells202642782813PubTator, text miningPubMed
Nuclear-targeted GDOWN1 potently suppresses tumors by inducing premature transcription termination and exporting Pol Ⅱ CTD phosphatases to activate RB.Cell Death Differ202642649379PubTator, text miningPubMed
Nucleolar and coiled-body phosphoprotein 1 enhances the induction of CYP3A4 by promoting nuclear translocation of pregnane X receptor.Drug Metab Dispos202642526206PubTator, text miningPubMed
Preferential Upregulation of AMOT-p80 Is Associated with YAP-Linked Resistance to 5-Fluorouracil and Oxaliplatin in Colorectal Cancer Cells.Biomolecules202642352235PubTator, text miningPubMed
CircNOLC1/KRT16 promotes colorectal cancer invasion and migration via c-met nuclear translocation and reprogramming of the oxidative pentose phosphate pathway.J Biol Chem202641861993PubTator, text miningPubMed
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.Proc Natl Acad Sci U S A202641860961PubTator, text miningPubMed
Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments.Int J Mol Sci202641751791PubTator, text miningPubMed
Beyond Ion Channels: Emerging Roles of FGF12 in Cellular Regulation and Cancer Progression.Cells202641744813PubTator, text miningPubMed
PFKP binding AMOTL1 promotes tumor aerobic glycolysis and epithelial-mesenchymal transition by modulating Hippo pathway in head and neck cancer.J Transl Int Med202641727965PubTator, text miningPubMed

1 to 10 of 1,561

See all 1,561 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/9221

GET https://conductscience.org/api/genes/v1/9221/patents